Peptilogics Raises $78M in Series B2 Round Led by Presight Capital, Thiel Bio and Founders Fund

Deal Summary

Peptilogics, a clinical-stage biotech developing surgical therapeutics to prevent medical device infections, closed a $78M Series B2 financing. The round was led by Presight Capital, Thiel Bio and Founders Fund, with participation from AMR Action Fund, Narya Capital and Beyond Ventures.